Alnylam vs. Ionis: Here's the Better Bad-News Buy
Key PointsAlnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.